Figure 2.
Survival curves for patients with well-moderately carcinoma with C-erbB-2 amplification (n = 17) and for those with no C-erbB-2 amplification (n = 28, P < 0.05).
Survival curves for patients with well-moderately carcinoma with C-erbB-2 amplification (n = 17) and for those with no C-erbB-2 amplification (n = 28, P < 0.05).